Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/13163
Title: Somatostatin: physiology and clinical applications.
Authors: Shulkes, Arthur
Affiliation: Department of Surgery, University of Melbourne, Austin Hospital, Victoria, Australia.
Issue Date: 1-Jan-1994
Citation: Baillie`re's Clinical Endocrinology and Metabolism; 8(1): 215-36
Abstract: Somatostatin (SOM) was originally isolated as the hypothalamic inhibitor of growth hormone release but was subsequently shown to have a widespread distribution including the gastrointestinal tract. In fact the gastrointestinal tract contains about 70% of the total body SOM. SOM has inhibitory actions on gastrointestinal exocrine and endocrine secretions, motility and blood flow. Within the gut it functions as an endocrine, paracrine, autocrine and neurocrine factor. SOM is released by a meal, and a number of neurotransmitters and regulatory peptides also influence SOM release. SOM is a key component of the gastrin-acid feedback loop as luminal acid releases SOM, which in turn has inhibitory effects on both gastrin and gastric acid. Consistent with the diverse functions of SOM, a number of different although related SOM receptors with distinct distribution patterns and intracellular mediators have been cloned and sequenced. SOM is the first of the gut regulatory peptides to have a significant therapeutic use. By inhibiting both the target cell (e.g. parietal cell) and the release of the active agent (e.g. gastrin) the therapeutic potential of SOM is magnified. To date most of the clinical experience has been with the one analogue, octreotide. This analogue has a longer half-life than SOM (hours versus minutes) but has only minimal oral activity, therefore requiring subcutaneous injections several times a day. The definite gastrointestinal applications include treatment of gastroenteropancreatic tumours. It is also becoming a favoured treatment for gastrointestinal fistulae, variceal bleeding and diarrhoea. However, octreotide has no consistent effect on tumour growth. The high density of SOM receptors on tumours has allowed localization of tumours using in vivo scintography with labelled octreotide. The sequencing of a variety of SOM receptors with different distributions and differing cellular effector systems raises the likelihood of developing SOM analogues for specific clinical applications.
Internal ID Number: 7907862
URI: http://ahro.austin.org.au/austinjspui/handle/1/13163
URL: http://www.ncbi.nlm.nih.gov/pubmed/7907862
Type: Journal Article
Subjects: Amino Acid Sequence
Animals
Base Sequence
Digestive System Physiological Phenomena
Gastrointestinal Diseases.drug therapy
Humans
Molecular Sequence Data
Octreotide.therapeutic use
Receptors, Somatostatin.physiology
Signal Transduction
Somatostatin.biosynthesis.genetics.physiology.secretion
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.